Participant flow

Bupropion Hydrochloride in Improving Sexual Desire in Women With Breast or Gynecologic Cancer · Source last updated 2026-07-10

Results reported by the registry submitting party. Population, time horizon, units and missing values must be read together.

groups

1. description

   One Bupropion 150 mg XL capsule by mouth (PO) in a.m. daily for one week; one Bupropion 150 mg XL capsule and one placebo capsule PO in a.m. daily for 8 weeks; one placebo capsule daily PO in a.m. for one 1 week (titration off).

   id

   FG000

   title

   Bupropion 150 mg

2. description

   One Bupropion 150 mg XL capsule PO in a.m. daily for one week; two Bupropion 150 mg XL capsules PO in a.m. daily for 8 weeks (300 mg target dose); one Bupropion 150 mg XL capsule PO in a.m. daily for 1 week (titration off)

   id

   FG001

   title

   Bupropion 300 mg

3. description

   One placebo capsule PO in a.m. daily for 1 week; two placebo capsules PO in a.m. daily for 8 weeks; one placebo capsule PO in a.m. daily for 1 week (titration off)

   id

   FG002

   title

   Placebo

periods

1. milestones

   1. achievements

      1. group Id

         FG000

         num Subjects

         79

      2. group Id

         FG001

         num Subjects

         74

      3. group Id

         FG002

         num Subjects

         77

      type

      STARTED

   2. achievements

      1. group Id

         FG000

         num Subjects

         79

      2. group Id

         FG001

         num Subjects

         74

      3. group Id

         FG002

         num Subjects

         77

      type

      Eligible Population

   3. achievements

      1. group Id

         FG000

         num Subjects

         77

      2. group Id

         FG001

         num Subjects

         73

      3. group Id

         FG002

         num Subjects

         76

      comment

      Eligible participants with adverse event data who started study treatment.

      type

      Adverse Event Population

   4. achievements

      1. group Id

         FG000

         num Subjects

         79

      2. group Id

         FG001

         num Subjects

         74

      3. group Id

         FG002

         num Subjects

         77

      comment

      Participants contributing data to results are considered to have completed the study.

      type

      COMPLETED

   5. achievements

      1. group Id

         FG000

         num Subjects

         0

      2. group Id

         FG001

         num Subjects

         0

      3. group Id

         FG002

         num Subjects

         0

      type

      NOT COMPLETED

   title

   Overall Study

pre Assignment Details

Registered patients who completed required baseline assessments were randomized. Of 238 registered patients, 230 were randomized.

Download exact source JSON → · Snapshot ctgov-results-25a395029948b04d52b1253f

Preserved source evidence · Not medical advice